J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
2022 saw just 19 initial public offerings of drug developers, the lowest total since 2012.
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.